| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 4.57▲ | 4.51▲ | 4.48▲ | 4.48▲ | 4.45▲ |
| MA10 | 4.54▲ | 4.47▲ | 4.47▲ | 4.42▲ | 4.42▲ |
| MA20 | 4.51▲ | 4.47▲ | 4.49▲ | 4.49▲ | 4.19▲ |
| MA50 | 4.47▲ | 4.47▲ | 4.41▲ | 4.45▲ | N/A |
| MA100 | 4.47▲ | 4.40▲ | 4.40▲ | 4.18▲ | N/A |
| MA200 | 4.47▲ | 4.41▲ | 4.52▲ | 6.74▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.007▲ | 0.009▲ | 0.001▲ | 0.006▲ | 0.674▲ |
| RSI | 62.580▲ | 67.400▲ | 64.026▲ | 53.983▲ | 36.958▼ |
| STOCH | 82.928▲ | 79.327 | 53.293 | 73.999 | 57.747 |
| WILL %R | -20.000▲ | -12.821▲ | -12.821▲ | -10.204▲ | -27.869 |
| CCI | 88.191 | 256.667▲ | 261.364▲ | 101.640▲ | 54.078 |
|
Friday, August 15, 2025 08:17 AM
Following successful completion of the Phase 1 study, with initial SAD data expected by year-end 2025, BioAge plans to advance BGE-102 into a proof-of-concept study in obesity in 2026, with top-line ...
|
|
Friday, August 15, 2025 06:19 AM
First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with pote ...
|
|
Thursday, August 07, 2025 03:14 AM
Key Points Revenue (GAAP) reached $2.41 million for Q2 2025, sharply beating the analyst estimate of zero. Net loss per share (GAAP) was $(0.60) for Q2 2025, with total net loss (GAAP) increasing to ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 15/08/25 | 4.50 | 4.60 | 4.40 | 4.55 | 197,300 |
| 14/08/25 | 4.50 | 4.52 | 4.43 | 4.46 | 53,665 |
| 13/08/25 | 4.48 | 4.58 | 4.47 | 4.56 | 103,200 |
| 12/08/25 | 4.35 | 4.50 | 4.33 | 4.48 | 91,996 |
| 11/08/25 | 4.31 | 4.36 | 4.25 | 4.34 | 67,100 |
| 08/08/25 | 4.34 | 4.347 | 4.2702 | 4.33 | 44,200 |
| 07/08/25 | 4.41 | 4.43 | 4.262 | 4.32 | 58,300 |
| 06/08/25 | 4.42 | 4.42 | 4.307 | 4.33 | 35,764 |
| 05/08/25 | 4.42 | 4.455 | 4.35 | 4.44 | 71,300 |
| 04/08/25 | 4.15 | 4.43 | 4.12 | 4.42 | 87,955 |
|
|
||||
|
|
||||
|
|